No abstract

A483 (75 patients each). The 75 patients on our intervention group were educated by the Pharmacist on diabetes and hypertension, their complications, risks, preventive measures and management. This was done at least six times during the study period unlike the control group who received no such education. In particular, they were counseled on the need for medication and treatment adherence such as clinic visits, and life style modifications including diet and exercise. Outcome measure included changes in fasting blood sugar (FBS), blood pressure (BP), body mass index (BMI) and adherence to instructions. Results: There were no statistical differences between the baseline and 6 months data of the control group as mean fasting blood sugar were 162.2 ± 69.1 and 159.9 ±57.2 (P= 0.825) and mean systolic blood pressure of 144.7 ± 23.8 and 145.5±18.6 (P= 0.819) respectively. The intervention group had mean fasting blood sugar of 156.7 ± 30.5 and 131.8± 40.4 (P< 0.001) and mean systolic blood pressure of 146.4 ± 13.9 and 133.8 ± 18.5 (P< 0.001) respectively. Adherence levels to medication taking in the groups were 42.7% : 94.7% respectively (P= 0.001). ConClusions: In diabetes management, patient education and counseling have become key tools in achieving both glycaemic and blood pressure control.

Multiple myeloma (MM) is a hematological neoplastic plasma-cell disorder in the bone marrow. Nowadays, the survival of MM patients has improved by using novel therapies (e.g., bortezomib, thalidomide). Decision-analytic models (DAM) are known to be very useful in guiding clinical and health policy decisions by systematically evaluating expected outcomes of alternative treatments. When conducting DAM, it is recommended by National Institute for Clinical Excellence (NICE) as the preferred framework to use qualityadjusted life years as the main measure for health outcomes derived from generic preference-based instruments. The objective of our study was to identify and analyze the structural and methodological approaches of published studies that evaluated: (1) DAM for various treatment strategies in MM and (2) published health utility values (HUVs) after MM treatment. The searches were developed in the electronic literature database PubMed/MEDLINE. Additionally, we aimed to derive real-world data for HUVs from the current patients’ treatment landscape in the Hematology Clinical Center in Skopje. The survey collecting national HUVs was conducted during the period January-November 2016, using the generic preference-based instrument EQ-5D-5L, administered at one-time point in 20 MM patients. Only five studies reported on using a DAM. Seven studies were included in the extraction of already published HUVs. The calculated national health utility score of 0.723 was comparable to the published data in the previously identified studies reporting on similar MM treatment protocols. Several modeling approaches and HUVs, developed for different treatment strategies and target groups in MM were identified. Those data could be used to parameterize a DAM for MM treatment.

No abstract